Given that cisplatin is widely used for chemotherapy across various tumours, the renoprotective effects of PCI‐34051 identified in this study suggest a promising possibility: targeting HDAC8 may enhance the anti‐tumour effects of cisplatin while simultaneously protecting the kidneys during cisplatin chemotherapy‐achieving the goal of ‘killing two birds with one stone.’ Here, HDAC8 is linked to neoplasm.